|
gptkbp:instanceOf
|
monoclonal antibody cocktail
|
|
gptkbp:administeredBy
|
post-exposure prophylaxis
multiple doses
single dose
non-hospitalized COVID-19 patients
|
|
gptkbp:alsoKnownAs
|
gptkb:casirivimab/imdevimab
|
|
gptkbp:approvedBy
|
gptkb:Japan
gptkb:United_Kingdom
|
|
gptkbp:ATCCode
|
gptkb:J06BD08
|
|
gptkbp:category
|
antiviral drug
immunotherapy
|
|
gptkbp:developedBy
|
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:EUAGrantedDate
|
2020-11-21
|
|
gptkbp:firstDescribed
|
2020
|
|
gptkbp:hasComponent
|
gptkb:casirivimab
gptkb:imdevimab
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
REGEN-COV
|
|
gptkbp:legalStatus
|
gptkb:emergency_use_authorization
conditional approval
|
|
gptkbp:marketedAs
|
gptkb:Roche_(outside_US)
|
|
gptkbp:mechanismOfAction
|
binds to SARS-CoV-2 spike protein
blocks virus entry into human cells
|
|
gptkbp:notEffectiveAgainst
|
gptkb:Omicron_variant
|
|
gptkbp:notRecommendedFor
|
hospitalized patients requiring oxygen
patients with severe COVID-19
|
|
gptkbp:patent
|
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:receivedEUAFrom
|
gptkb:U.S._Food_and_Drug_Administration
|
|
gptkbp:routeOfAdministration
|
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
nausea
pruritus
rash
allergic reactions
infusion-related reactions
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:type
|
gptkb:drug
|
|
gptkbp:usedFor
|
gptkb:COVID-19
COVID-19 prevention
|
|
gptkbp:WHODrugCode
|
10000074222
|
|
gptkbp:bfsParent
|
gptkb:Regeneron
|
|
gptkbp:bfsLayer
|
6
|